Marizyme IncOTCQB:MRZM
- LAST PRICE0.0950
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0950
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 16, 2024
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM), from 7:08AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:08AM ET on Tuesday Apr 16, 2024 by Dow JonesMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM), from 7:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Marizyme Inc | 4.4M | -0.1x | --- |
Manuka Inc | 4.5M | -3.1x | --- |
Palisade Bio Inc | 5.3M | -0.2x | --- |
Halberd Corp | 5.1M | 3.5x | --- |
Regen BioPharma Inc | 3.0M | -2.0x | --- |
Artelo Biosciences Inc | 4.3M | -0.4x | --- |
Company Information
Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.
Contact Information
- Headquarters
- 555 HERITAGE DRIVE, SUITE 205JUPITER, FL, United States 33458
- Phone
- 561-935-9955
- Fax
- 770-720-1335
Executives
- Director
- Vithalbhai Dhaduk
- Chief Executive Officer, Secretary, Director
- David Barthel
- Chief Financial Officer, Treasurer
- George Kovalyov
- Executive Vice President, Chief Scientific Officer
- Catherine Pachuk
- Vice President - Finance
- Harrison Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
|---|---|
Revenue (TTM) | $590.9K |
Shares Outstanding | 46.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-1.83 |
Book Value | $0.43 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,551.63% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
